An observational study in Beta-lactamase Extended Spectrum, E. Coli, Elderly, Mortality, Risk Factor, sponsored by Nantes University Hospital. Completed at 1 site in France. Open to participants aged 65 Years to 105 Years. Per ClinicalTrials.gov, last updated 2021-09-21.
Sponsored by Nantes University Hospital · Observational
In the US and Europe, bacteremia are ranked the 7th leading cause of death from all causes. E. coli is one of the main microorganism involved, responsible for 30% to 45% of bacteremia. In Europe, bacteremia E. coli, including BLSE phenotype, have a strong impact on public health, causing increased mortality, particularly in the elderly, and an increase in the average hospital stay. However, few studies have specifically concerned with the criteria associated with mortality of elderly patients with BLSE E. coli bacteremia. Finally, improving epidemiological knowledge of the elderly patients with bacteremia due to BLSE E. coli has importance in terms of public health and is a prerequisite to the development of preventive strategies and to improve the short-term prognosis.
322 studies on the registry are indexed under Bacteremia; 49 are open to participants now.
This study's enrollment of 144 is below the median of 269 across 133 observational studies indexed under Bacteremia.
Browse Bacteremia studies →Nantes University Hospital is the lead sponsor of 825 studies on the registry; 195 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All data concerning blood cultures analyzed in the bacteriology department of University Hospital of Nantes are stored digitally, particularly E. coli ESBL. Thus, the extraction of these data will allow the retrospective inclusion of patients and enhance the feasibility of the study.
All patients with positive blood culture E. coli BLSE will be included in the study. Bacteremia E. coli BLSE will be defined as the identification of one or more blood cultures positive for E. coli BLSE in patients with clinical criteria of systemic inflammatory response, at least two of the following 4 criteria:
Exclusion Criteria:
Association between advancing age and mortality at 30 days in patients with bacteremia E. coli beta-lactamase phenotype extended spectrum.
Time frame: 30 days
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nantes University Hospital